INT240280

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2008
Last Reported 2010
Negated 0
Speculated 3
Reported most in Body
Documents 14
Total Number 19
Disease Relevance 20.38
Pain Relevance 0.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IGFALS) extracellular space (IGFALS) extracellular region (IGFALS)
cell adhesion (IGFALS) nucleolus (IGFALS) nucleus (IGFALS)
Anatomy Link Frequency
motor neuron 2
row 1
B12 1
IGFALS (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 39 97.44 Very High Very High Very High
peripheral neuropathy 10 93.76 High High
Spinal cord 73 93.04 High High
medulla 28 82.00 Quite High
imagery 69 75.52 Quite High
Action potential 10 72.80 Quite High
Pain 10 46.44 Quite Low
peptic ulcer disease 5 20.28 Low Low
Transcranial magnetic stimulation 20 5.00 Very Low Very Low Very Low
Multiple sclerosis 16 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Motor Neuron Diseases 1770 100.00 Very High Very High Very High
Disease 545 100.00 Very High Very High Very High
Syndrome 131 100.00 Very High Very High Very High
Hypercalcemia 190 99.96 Very High Very High Very High
Disease Progression 117 98.12 Very High Very High Very High
Congenital Anomalies 57 98.00 Very High Very High Very High
INFLAMMATION 39 97.44 Very High Very High Very High
Megaloblastic Anemia 5 97.20 Very High Very High Very High
Gliosis 18 96.96 Very High Very High Very High
Glossitis 5 95.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The subcutaneously administration of rhIGF1 does not correct the low circulating levels of IGFBP-3 and ALS and therefore the clearance of rhIGF1 is accelerated and the tissue distribution affected.33 Moreover, it has been described that prolonged administration of rhIGF1 leads to generation of IGFBP-3 and ALS and other binding proteins, requiring sometimes a reduction of rhIGF1 dosage to prevent adverse effects.2 The possible direct effect of GH on skeletal growth should also be considered.
Gene_expression (levels) of ALS
1) Confidence 0.42 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.05 Pain Relevance 0
The subcutaneously administration of rhIGF1 does not correct the low circulating levels of IGFBP-3 and ALS and therefore the clearance of rhIGF1 is accelerated and the tissue distribution affected.33 Moreover, it has been described that prolonged administration of rhIGF1 leads to generation of IGFBP-3 and ALS and other binding proteins, requiring sometimes a reduction of rhIGF1 dosage to prevent adverse effects.2 The possible direct effect of GH on skeletal growth should also be considered.
Gene_expression (generation) of ALS
2) Confidence 0.42 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.07 Pain Relevance 0
Vitamin B12 levels and MND/ALS
Gene_expression (levels) of MND/ALS in B12 associated with motor neuron diseases
3) Confidence 0.39 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2941760 Disease Relevance 2.31 Pain Relevance 0.09
However, it is well recognised that a significant number of patients who either have a pure LMN syndrome or who early in the course of the disease do not have obvious UMN signs, will undoubtedly have ALS (or a variant) but will not fall into these categories in the revised criteria.
Gene_expression (recognised) of ALS associated with syndrome, disease and motor neuron diseases
4) Confidence 0.38 Published 2009 Journal Orphanet J Rare Dis Section Body Doc Link PMC2656493 Disease Relevance 0.78 Pain Relevance 0.03
Despite advances in investigative medicine over the past century, the diagnosis of ALS is based on the presence of very characteristic clinical findings in conjunction with investigations to exclude "ALS-mimic" syndromes (e.g.
Gene_expression (syndromes) of ALS-mimic associated with syndrome and motor neuron diseases
5) Confidence 0.38 Published 2009 Journal Orphanet J Rare Dis Section Body Doc Link PMC2656493 Disease Relevance 1.37 Pain Relevance 0.18
There is ongoing debate as to whether this syndrome is in fact an entirely separate disorder to ALS, but there is evidence from pathological studies that hallmarks of ALS such as ubiquitinated inclusions are present in this condition.
Gene_expression (present) of ALS associated with syndrome and motor neuron diseases
6) Confidence 0.38 Published 2009 Journal Orphanet J Rare Dis Section Body Doc Link PMC2656493 Disease Relevance 1.52 Pain Relevance 0
Despite advances in investigative medicine over the past century, the diagnosis of ALS is based on the presence of very characteristic clinical findings in conjunction with investigations to exclude "ALS-mimic" syndromes (e.g.
Gene_expression (diagnosis) of ALS associated with syndrome and motor neuron diseases
7) Confidence 0.38 Published 2009 Journal Orphanet J Rare Dis Section Body Doc Link PMC2656493 Disease Relevance 1.39 Pain Relevance 0.18
The ALS syndrome progressed despite therapy.
Gene_expression (syndrome) of ALS associated with syndrome and motor neuron diseases
8) Confidence 0.34 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2941760 Disease Relevance 1.30 Pain Relevance 0
The working diagnosis at this point was motor neuron disease (MND) probably secondary to ALS (or 'clinically possible ALS', via El Escorial criteria).
Spec (possible) Gene_expression (possible) of ALS in motor neuron associated with motor neuron diseases
9) Confidence 0.34 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2941760 Disease Relevance 1.00 Pain Relevance 0.07
The working diagnosis at this point was motor neuron disease (MND) probably secondary to ALS (or 'clinically possible ALS', via El Escorial criteria).
Spec (possible) Gene_expression (possible) of ALS in motor neuron associated with motor neuron diseases
10) Confidence 0.34 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2941760 Disease Relevance 1.01 Pain Relevance 0.07
However, the p-values were reduced for the ALS vs. mimic disease control subgroup comparison (Table 3, first row) relative to the ALS vs. all disease control subgroup comparison (Table 2, “ALS vs.
Gene_expression (reduced) of ALS in row associated with disease and motor neuron diseases
11) Confidence 0.28 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 1.91 Pain Relevance 0
We collected at least three longitudinal CSF draws from 15 ALS patients over a 1–2 year time period for each patient.
Gene_expression (draws) of ALS associated with motor neuron diseases
12) Confidence 0.28 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.76 Pain Relevance 0
A recent study examined a single CSF draw per ALS patient, taken at varying times from symptom onset, to indirectly infer the average longitudinal change in cystatin C concentration in the group as a whole, and they reported that cystatin C levels do not change over time [16].
Spec (examined) Gene_expression (draw) of ALS associated with motor neuron diseases
13) Confidence 0.28 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 1.20 Pain Relevance 0.05
In summary, we have completed a comprehensive evaluation of cystatin C as a candidate ALS biomarker, including assessments of two complementary measures of cystatin C in two distinct biofluids as well as examinations of both longitudinal CSF samples and patient survival data.
Gene_expression (biomarker) of ALS associated with motor neuron diseases
14) Confidence 0.28 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000338 Disease Relevance 0.85 Pain Relevance 0
For example, Adam, an ALS patient considering the use of a breathing assistance device—bilevel positive airway pressure (BiPAP)—asked the following:
Gene_expression (patient) of ALS associated with motor neuron diseases
15) Confidence 0.22 Published 2008 Journal Journal of Medical Internet Research Section Body Doc Link PMC2553248 Disease Relevance 0.10 Pain Relevance 0
Although there are interesting correlations between PHP and SHP, MND/ALS with aberrant calcium, vitamin D, and PTH metabolism, most of the literature does not indicate a conclusive relationship between ALS and PHP/SHP and treatment of PHP/SHP does not lead to improvement of MND.


Gene_expression (metabolism) of MND/ALS associated with hypercalcemia and motor neuron diseases
16) Confidence 0.15 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2941760 Disease Relevance 2.32 Pain Relevance 0.07
This concept was already approached by Kaiser and colleagues [44], who observed a progressive loss of Kir4.1 and a slight increase in AQP4 protein in the mouse ALS model.
Gene_expression (model) of ALS associated with motor neuron diseases
17) Confidence 0.10 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.80 Pain Relevance 0.09
Taken together, these data corroborate evidences of AQPs involvement in BBB disruption in animal models of ALS.
Gene_expression (disruption) of ALS associated with motor neuron diseases
18) Confidence 0.10 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.20 Pain Relevance 0.13
Kaplan–Meier survival curves from patients with fALS-causing SOD1 mutations, non-SOD1-related fALS, and sALS were generated.
Gene_expression (generated) of fALS
19) Confidence 0.10 Published 2008 Journal PLoS Biology Section Body Doc Link PMC2486295 Disease Relevance 0.43 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox